

Helix BioMedix Announces U.S. Patent Issuance for Cosmetic Compositions Containing Short Bioactive Peptides

Patent Covers Peptides Included in More than Twenty Commercially Available Products

Apr 10, 2008 - Bothell, Washington

Helix BioMedix, Inc. (OTCBB: HXBM - News), a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,354,903 by the United States Patent and Trademark Office.

The patent covers more than eighty proprietary peptides for use in cosmetic and skin care applications and products. There are currently over 20 marketed products using peptides protected under the patent including such cosmeceutical brands as Fusion Beauty, Smashbox, Isomers, and B. Kamins. Numerous additional product roll outs are planned for later this year.

"The issuance of this patent is a key step in the protection of the intellectual property associated with our proprietary peptides, which is of critical importance to the company," stated R. Stephen Beatty, President and CEO of Helix BioMedix, Inc. "While our primary focus is dermatological therapeutic development, this represents our first issued patent specifically targeting cosmetic and skin care applications, which is the direct result of our efforts to diversify our sequences as well as their bioactivities and application. We currently have additional patent applications filed targeting the skin care market, which we hope will continue the expansion of the company's proprietary library of bioactive peptides over the next several years."

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with over 50 patents supporting an extensive library of peptides that are diverse in structure, sequence, and bioactivity. We are a leader in creating novel, first in class, lipohexapeptide drug candidates, with an initial focus on the large topical anti-infective market including indications such as acne, rosacea, MRSA and fungal infections. We are also focusing on the design of peptides for the consumer market where, to date, we have entered into partnerships with six companies engaged in supplying high-quality ingredients to the cosmetic and cosmeceutical sectors. Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take peptide-based products from a theoretical concept to a safe and efficacious finished product.

More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Forward Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital,

enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Helix BioMedix Contacts:

Company Contact:

R. Stephen Beatty

President and CEO

425-402-8400

sbeatty@helixbiomedix.com

Investor Contact:

Ryan Bright

Shelton Group Investor Relations

972-239-5119 X 159

rbright@sheltongroup.com